A 45-year-old man with poorly controlled diabetes and chronic sinusitis presents with acute right eye pain, proptosis, and chemosis. On examination, he has restricted eye movements and a mid-dilated pupil that does not react to light. Fundoscopy shows retinal whitening and optic disc swelling. CT orbit shows infiltration of the right cavernous sinus with gas bubbles in the orbital fat. Blood glucose is 480 mg/dL. What is the most likely diagnosis, and which organism is classically associated?

Explanation

## Clinical Diagnosis: Rhinocerebral Mucormycosis ### Key Clinical Features **High-Yield:** The triad of **uncontrolled diabetes + gas in orbit + rapid cavernous sinus involvement** is pathognomonic for mucormycosis. ### Risk Factors & Epidemiology | Risk Factor | Mechanism | Relevance | | --- | --- | --- | | Uncontrolled diabetes (DKA/HHS) | Impaired neutrophil function, elevated glucose | Most common risk factor | | Hematologic malignancy | Immunosuppression | Second most common | | Solid organ/stem cell transplant | T-cell depletion | High risk | | Prolonged corticosteroid use | Immune dysregulation | Moderate risk | **Clinical Pearl:** This patient's blood glucose of 480 mg/dL with poor glycemic control is the critical predisposing factor. Mucormycosis is an opportunistic infection that thrives in hyperglycemic, acidotic states. ### Pathognomonic Features of Orbital Mucormycosis 1. **Gas in orbital fat** (angioinvasion → tissue necrosis → gas-forming organisms) 2. **Rapid progression** to cavernous sinus thrombosis (within days) 3. **Ophthalmoplegia** with mid-dilated pupil (CN III palsy from cavernous sinus involvement) 4. **Retinal whitening** (cotton-wool spots from retinal ischemia due to vascular invasion) 5. **Black necrotic tissue** in nasal mucosa or palate (pathognomonic but late sign) ### Organism Identification **Mnemonic:** **RHIZOMUCOR** — The three most common causative agents: - **R**hizopus species (60–70% of cases) - **M**ucor species (20–30%) - **R**hizomucor species (5–10%) All are **angioinvasive** fungi that cause: - Vascular thrombosis → tissue necrosis - Rapid spread to sinuses, orbit, brain - Fulminant course without urgent intervention ### Pathophysiology ```mermaid flowchart TD A[Uncontrolled diabetes + hyperglycemia]:::outcome --> B[Impaired neutrophil chemotaxis & phagocytosis]:::outcome B --> C[Inhalation of fungal spores]:::outcome C --> D[Colonization of nasal/sinus mucosa]:::outcome D --> E[Angioinvasion by fungal hyphae]:::action E --> F[Vascular thrombosis + tissue necrosis]:::urgent F --> G[Gas production in necrotic tissue]:::urgent F --> H[Rapid spread to orbit & cavernous sinus]:::urgent H --> I[Ophthalmoplegia, vision loss, death]:::urgent ``` ### Diagnostic Approach **Key Point:** Diagnosis requires: 1. **High clinical suspicion** (diabetes + rapid orbital cellulitis + gas on imaging) 2. **Tissue biopsy** with histopathology (broad, non-septate hyphae with right-angle branching) 3. **Culture** (slow-growing; may take weeks) 4. **Imaging:** CT/MRI showing gas, necrosis, cavernous sinus involvement ### Management Algorithm ```mermaid flowchart TD A[Suspected mucormycosis]:::outcome --> B[Urgent ENT + Ophthalmology + ID consult]:::action B --> C[Tissue biopsy from involved site]:::action C --> D[Start IV liposomal amphotericin B immediately]:::action D --> E[Aggressive glycemic control]:::action E --> F[Urgent surgical debridement]:::action F --> G[Repeat debridement as needed]:::action G --> H[Switch to oral posaconazole after stabilization]:::action ``` ### Antifungal Therapy **High-Yield:** Treatment is **aggressive and multimodal**: 1. **IV Liposomal Amphotericin B** - Dose: 10 mg/kg/day IV - Start immediately (do NOT wait for culture confirmation) - Continue until clinical improvement, then switch to posaconazole 2. **Oral Posaconazole** (maintenance after IV induction) - Dose: 300 mg daily in divided doses - Duration: Months to years depending on extent 3. **Aggressive Glycemic Control** - Insulin therapy to achieve glucose <200 mg/dL - Correct metabolic acidosis if present - Critical for immune recovery ### Surgical Management **Warning:** Surgery is **mandatory** and often requires **multiple debridements**: - Endoscopic sinus debridement (remove all necrotic tissue) - Orbital debridement if abscess present - Repeat procedures every 48–72 hours until no new necrosis ### Prognosis **Clinical Pearl:** Even with aggressive treatment, mortality is 20–50% in diabetic patients with cavernous sinus involvement. Early recognition and immediate intervention are critical for vision and life preservation. [cite:Kanski Clinical Ophthalmology 9e Ch 6; Harrison 21e Ch 199]